

**Defiance Daily Target 2X Long NVO ETF**  
**Schedule of Investments**  
**January 31, 2026 (Unaudited)**

<b>U.S. TREASURY BILLS - 7.5%</b>	<b>Principal</b>	<b>Value</b>
3.58%, 02/19/2026 <sup>(a)(b)</sup>	\$ 5,990,000	\$ 5,979,834
<b>TOTAL U.S. TREASURY BILLS (Cost \$5,979,320)</b>		<u>5,979,834</u>
<hr/>		
<b>MONEY MARKET FUNDS - 7.0%</b>	<b>Shares</b>	
First American Government Obligations Fund - Class X, 3.61% <sup>(c)</sup>	5,657,278	5,657,278
<b>TOTAL MONEY MARKET FUNDS (Cost \$5,657,278)</b>		<u>5,657,278</u>
<hr/>		
<b>TOTAL INVESTMENTS - 14.5%</b> (Cost \$11,636,598)		11,637,112
Other Assets in Excess of Liabilities - 85.5%		68,800,493
<b>TOTAL NET ASSETS - 100.0%</b>		<u>\$ 80,437,605</u>

Percentages are stated as a percent of net assets.

- (a) The rate shown is the annualized yield as of January 31, 2026.
- (b) All or a portion of the security has been pledged as collateral for swap contracts. The fair value of assets committed as collateral as of January 31, 2026 was \$5,629,414.
- (c) The rate shown represents the 7-day annualized yield as of January 31, 2026.

**Defiance Daily Target 2X Long NVO ETF**  
**Schedule of Total Return Swap Contracts**  
**January 31, 2026 (Unaudited)**

<b>Reference Entity</b>	<b>Counterparty</b>	<b>Pay/ Receive Reference Entity</b>	<b>Financing Rate</b>	<b>Payment Frequency</b>	<b>Maturity Date</b>	<b>Notional Amount</b>	<b>Value/ Unrealized Appreciation (Depreciation)</b>
Novo Nordisk AS	BMO Capital Markets Corp.	Receive	OBFR + 15.00%	Termination <sup>(a)</sup>	01/04/2026	\$ 20,206,200	\$ 3,845,400
Novo Nordisk AS	Cantor Fitzgerald & Co.	Receive	OBFR + 5.00%	Termination <sup>(a)</sup>	09/08/2028	18,967,203	4,614,938
Novo Nordisk AS	Clear Street LLC Marex Capital Markets Inc.	Receive	OBFR + 1.25%	Termination <sup>(b)</sup>	08/25/2026	22,619,652	5,353,472
Novo Nordisk AS	Morgan Stanley	Receive	OBFR + 3.00%	Monthly <sup>(b)</sup>	09/25/2026	17,400,866	4,233,830
Novo Nordisk AS	National Bank of Canada Financial, Inc.	Receive	OBFR + 3.50%	Termination <sup>(a)</sup>	10/06/2028	57,647,100	13,643,694
Novo Nordisk AS	Nomura Securities International, Inc.	Receive	OBFR + 5.00%	Termination <sup>(c)</sup>	01/31/2033	4,278,960	7,200
Novo Nordisk AS		Receive	OBFR + 7.00%	Termination <sup>(a)</sup>	12/13/2027	19,611,900	4,771,800
<b>Net Unrealized Appreciation (Depreciation)</b>							<b>\$ 36,470,334</b>

There are no upfront payments or receipts associated with total return swaps in the Fund as of January 31, 2026.

OBFR - Overnight Bank Funding Rate was 3.63% as of January 31, 2026.

- (a) Financing reset of the swap is effective on the last day of each month. Equity reset of the swap is effective on termination.
- (b) Financing reset of the swap is effective on the last day of each month. Equity reset of the swap is effective on termination, but also periodically throughout the term based on predetermined notional thresholds.
- (c) Financing reset of the swap is effective monthly. Equity reset of the swap is effective on termination, but also periodically throughout the term based on predetermined notional thresholds.

## Summary of Fair Value Disclosure as of January 31, 2026 (Unaudited)

Defiance Daily Target 2X Long NVO ETF (the "Fund") has adopted fair value accounting standards which establish a definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion of changes in valuation techniques and related inputs during the period, and expanded disclosure of valuation levels for major security types. These inputs are summarized in the three broad levels listed below. The inputs or valuation methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.

Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and based on the best information available.

The following is a summary of the fair valuation hierarchy of the Fund's securities as of January 31, 2026:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
<u>Investments:</u>				
U.S. Treasury Bills	\$ -	\$ 5,979,834	\$ -	\$ 5,979,834
Money Market Funds	5,657,278	-	-	5,657,278
Total Investments	<u>\$ 5,657,278</u>	<u>\$ 5,979,834</u>	<u>\$ -</u>	<u>\$ 11,637,112</u>
<u>Other Financial Instruments:</u>				
Total Return Swaps *	\$ -	\$ 36,470,334	\$ -	\$ 36,470,334
Total Other Financial Instruments	<u>\$ -</u>	<u>\$ 36,470,334</u>	<u>\$ -</u>	<u>\$ 36,470,334</u>

\* The fair value of the Fund's investment represents the unrealized appreciation (depreciation) as of January 31, 2026.

Refer to the Schedule of Investments for further disaggregation of investment categories.